Table 3.
Determinants of transfer: logistic regression results
| PCP-to-GE model | GE-to-PCP model | |||
|---|---|---|---|---|
| Odds ratio | 95% CI | Odds ratio | 95% CI | |
| New-onset GERD | 1.378 | (1.263–1.503)** | 1.153 | (1.039–1.279)** |
| Age | 0.996 | (0.993–0.999)* | 1.012 | (1.008–1.016)** |
| Male | 0.764 | (0.703–0.831)** | 0.932 | (0.846–1.027) |
| Pre-index date health status | ||||
| GERD severity | 0.942 | (0.840–1.056) | 0.849 | (0.757–0.951)** |
| Disorders of lipid metabolism | 1.062 | (0.953–1.183) | 1.010 | (0.894–1.140) |
| Hypertension | 0.851 | (0.760–0.953)** | 1.189 | (1.048–1.348)** |
| Respiratory infections | 0.962 | (0.872–1.062) | 1.017 | (0.907–1.140) |
| Disease of the heart | 1.052 | (0.938–1.181) | 0.920 | (0.808–1.046) |
| Other lower respiratory disease | 1.040 | (0.911–1.188) | 1.008 | (0.871–1.166) |
| Other gastrointestinal disorders | 1.118 | (0.949–1.316) | 1.131 | (0.969–1.322) |
| Lower gastrointestinal disorders | 1.196 | (0.929–1.540) | 1.169 | (0.922–1.483) |
| Other upper respiratory disease | 1.282 | (1.142–1.439)** | 0.950 | (0.831–1.085) |
| Any PPI use in first episode | 0.503 | (0.458–0.552)** | 0.595 | (0.531–0.667)** |
| Any H2RA use in first episode | 0.665 | (0.585–0.756)** | 0.820 | (0.691–0.974)* |
| Any other GERD therapy use in first episode | 1.034 | (0.842–1.271) | 0.817 | (0.679–0.983)* |
| Esophagitis in first episode | 1.573 | (1.299–1.905)** | 0.969 | (0.836–1.124) |
| Esophageal ulcer in first episode | 1.101 | (0.734–1.651) | 0.633 | (0.520–0.771)** |
| Esophageal stricture in first episode | 1.986 | (1.380–2.857)** | 0.947 | (0.774–1.159) |
| Barrett’s esophagus in first episode | 1.369 | (0.627–2.990) | 0.375 | (0.235–0.599)** |
| Endoscopy during first GE episode | – | – | 1.322 | (1.174–1.490)** |
| Observations (N) | 62,704 | 11,318 | ||
PCP primary care physician, GE gastroenterologist, PPI proton pump inhibitor, H2RA H2-receptor antagonist
* 0.01 ≤ P < 0.05; ** P < 0.01